Alkeran Articles

Ligand to earn up to $50 million in deal with Spectrum for Captisol-enabled melphalan

14 March 2013

First-line multiple myeloma patient share in Europe is variable by country

29 August 2012

Celgene swings back to profit in 1st qtr

5 May 2009

Celgene's 3rd-qtr profit triples on drug sales

17 November 2008

EC approves expanded indication for Velcade

15 September 2008

Millennium publishes results of VISTA trial

8 September 2008

JWCI to take part in Ph III Dulcuth trial

1 September 2008

Celgene profits double on rocketing sales

11 August 2008

Millennium/J&J's FDA approval for Velcade

30 June 2008

Celgene posts 1st-qtr loss on Pharmion costs

19 May 2008

EC clears Celgene's Thalidomide in MM

28 April 2008

Orphan status for Adherex product

3 March 2008

Celgene's

14 January 2008

Thalidomide improves survival rate in MM

15 October 2007

Celegene's 2nd-qtr 2007 income soars 187.2%

6 August 2007

Millennium initiates Ph III trial of Velcade

23 July 2007

Revlimid combo could become MM standard of care

18 June 2007

Celgene's 1st-qtr 2007 net income soars 61.4%

28 May 2007

EMEA accepts Pharmion's Thalidomide MA

12 March 2007

Pharmion submits thalidomide to EMEA

29 January 2007

Strong data for Pharmion's thalidomide in MM

19 June 2006

Millennium and J&J start Velcade Ph III study

17 January 2005

Celgene to distribute GSK myeloma drug

21 April 2003

Recent Japanese drug approvals for multinationals

24 April 2001

Thalomid trial in myeloma delayed?

9 April 2001

European launches for BI's TNF cancer drug - corrected story

16 September 1999

European launches for BI's TNF cancer drug

15 September 1999

Sandoz MDR Drug Shows Promise In Early Trials

13 November 1995

EXPANDING USES FOR INTERFERON ALPHA

31 May 1993

US APPROVAL FOR WELLCOME'S MIVACRON

10 February 1992

CHEMOTHERAPY STUDY

3 February 1992

Showing 1-31 of 31 articles

Go to beginningPrevious
  • 1
NextGo to end